Circulating tumour DNA analysis demonstrates spatial mutational heterogeneity that coincides with disease relapse in myeloma

Leukemia

Volumn 31, Issue 8, 2017, Pages 1695-1705

  Mithraprabhu, S ^a   Khong, T ^a   Ramachandran, M ^a   Chow, A ^b   Klarica, D ^c   Mai, L ^d   Walsh, S ^d   Broemeling, D ^d   Marziali, A ^d   Wiggin, M ^d   Hocking, J ^a,c   Kalff, A ^a,c   Durie, B ^e   Spencer, A ^a,c,f  

^a MONASH UNIVERSITY   (Australia)

^b Adelaide Cancer Centre   (Australia)

^c ALFRED HOSPITAL   (Australia)

^d Boreal Genomics Inc   (Canada)

^e CEDARS SINAI MEDICAL CENTER   (United States)

^f ALFRED HEALTH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; CELL DNA; CHLOROPLAST DNA; DNA; PROTEIN P53; KRAS PROTEIN, HUMAN; PROTEIN P21; RAS PROTEIN;

ARTICLE; BONE MARROW BIOPSY; CANCER PATIENT; CANCER RECURRENCE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DNA DETERMINATION; DROPLET DIGITAL POLYMERASE CHAIN REACTION; GENE MUTATION; GENETIC HETEROGENEITY; HUMAN; HUMAN CELL; HUMAN TISSUE; MULTIPLE MYELOMA; ONCOGENE K RAS; ONCOGENE N RAS; PRIORITY JOURNAL; BLOOD; CELL SEPARATION; GENETICS; MAPK SIGNALING; MUTATION; PHYSIOLOGY; RECURRENT DISEASE;

CELL SEPARATION; DNA, NEOPLASM; HUMANS; MAP KINASE SIGNALING SYSTEM; MULTIPLE MYELOMA; MUTATION; PROTO-ONCOGENE PROTEINS P21(RAS); RAS PROTEINS; RECURRENCE;

EID: 85007551377     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2016.366     Document Type: Article

References (22)

1. Kuehl WM, Bergsagel PL. Early genetic events provide the basis for a clinical classification of multiple myeloma. Hematology Am Soc Hematol Educ Program 2005; 1: 346-352.
2. Lohr JG, Stojanov P, Carter SL, Cruz-Gordillo P, Lawrence MS, Auclair D et al. Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy. Cancer Cell 2014; 25: 91-101.
3. Walker BA, Boyle EM, Wardell CP, Murison A, Begum DB, Dahir NM et al. Mutational spectrum, copy number changes, and outcome: results of a sequencing study of patients with newly diagnosed myeloma. J Clin Oncol 2015; 33: 3911-3920.
4. Egan JB, Shi CX, Tembe W, Christoforides A, Kurdoglu A, Sinari S et al. Wholegenome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides. Blood 2012; 120: 1060-1066.
5. Egan JB, Kortuem KM, Kurdoglu A, Izatt T, Aldrich J, Reiman R et al. Extramedullary myeloma whole genome sequencing reveals novel mutations in Cereblon, proteasome subunit G2 and the glucocorticoid receptor in multi drug resistant disease. Br J Haematol 2013; 161: 748-751.
6. Melchor L, Jones JR, Lenive O, Peterson EA, Brioli A, Murison A et al. Spatiotemporal analysis of intraclonal heterogeneity in multiple myeloma: unravelling the impact of treatment and the propagating capacity of subclones using whole exome sequencing. Blood 2015; 126: 371.
7. de Haart SJ, Willems SM, Mutis T, Koudijs MJ, van Blokland MT, Lokhorst HM et al. Comparison of intramedullary myeloma and corresponding extramedullary soft tissue plasmacytomas using genetic mutational panel analyses. Blood Cancer J 2016; 6: e426.
8. Forshew T, Murtaza M, Parkinson C, Gale D, Tsui DW, Kaper F et al. Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA. Sci Transl Med 2012; 4: 136ra168.
9. Murtaza M, Dawson SJ, Tsui DW, Gale D, Forshew T, Piskorz AM et al. Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature 2013; 497: 108-112.
10. Demetri GD, Jeffers M, Reichardt P, Kang YK, Blay JY, Rutkowski P et al. Mutational analysis of plasma DNA from patients (pts) in the phase III GRID study of regorafenib (REC) versus placebo (PL) in tyrosine kinase inhibitor (TKI)-refractory GIST: correlating genotype with clinical outcomes. J Clin Oncol 2013; 31: abstract 10503.
11. Kaedbey R, Kis O, Danesh A, Dowar M, Li TT, Li ZH et al. Noninvasive diagnosis of actionable mutations by deep sequencing of circulating tumor DNA in multiple myeloma. Clin Lymphoma Myeloma Leuk 2015; 15: e45-e46.
12. Rustad EH, Dai HY, Coward E, Misund K, Sundan A, Waage A. Detection and monitoring of BRAF and NRAS mutant clones in myeloma patients by digital PCR of circulating DNA. Blood 2015; 126: 4196.
13. Spencer A, Mithraprabhu S, Ramachandran M, Klarica D, Hocking J, Mai L et al. Evaluation of circulating tumour DNA for the mutational characterisation of multiple myeloma. Blood 2015; 126: 368.
14. Mithraprabhu S, Kalff A, Chow A, Khong T, Spencer A. Dysregulated class I histone deacetylases are indicators of poor prognosis in multiple myeloma. Epigenetics 2014; 9: 1511-1520.
15. Das K, Norton SE, Alt JR, Krzyzanowski GD, Williams TL, Fernando MR. Stabilization of cellular RNA in blood during storage at room temperature: a comparison of cell-free RNA BCT(R) with K3EDTA tubes. Mol Diagn Ther 2014; 18: 647-653.
16. Qin J, Williams TL, Fernando MR. A novel blood collection device stabilizes cellfree RNA in blood during sample shipping and storage. BMC Res Notes 2013; 6: 380.
17. Kidess E, Heirich K, Wiggin M, Vysotskaia V, Visser BC, Marziali A et al. Mutation profiling of tumor DNA from plasma and tumor tissue of colorectal cancer patients with a novel, high-sensitivity multiplexed mutation detection platform. Oncotarget 2015; 6: 2549-2561.
18. Beaver JA, Jelovac D, Balukrishna S, Cochran RL, Croessmann S, Zabransky DJ et al. Detection of cancer DNA in plasma of patients with early-stage breast cancer. Clin Cancer Res 2014; 20: 2643-2650.
19. Chesi M, Brents LA, Ely SA, Bais C, Robbiani DF, Mesri EA et al. Activated fibroblast growth factor receptor 3 is an oncogene that contributes to tumor progression in multiple myeloma. Blood 2001; 97: 729-736.
20. Kuehl WM, Bergsagel PL. Multiple myeloma: evolving genetic events and host interactions. Nat Rev Cancer 2002; 2: 175-187.
21. Liu P, Leong T, Quam L, Billadeau D, Kay NE, Greipp P et al. Activating mutations of N-and K-ras in multiple myeloma show different clinical associations: analysis of the Eastern Cooperative Oncology Group Phase III Trial. Blood 1996; 88: 2699-2706.
22. Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 2015; 348: 124-128.